WBI-2100: A Novel Anti-cancer Compound with Neutropenia-prevention Activity

WBI-2100 is being developed by Welichem as a treatment for solid cancers both as a monotherapy and synergistically in combination with other chemotherapies. Unlike other chemotherapeutic agents, WBI-2100 boosts neutrophil levels and prevents chemotherapy- induced neutropenia (CIN). There are no other anti-cancer drugs possessing such dual activities.

WBI-2100’s anti-cancer activity has been demonstrated in various mouse tumour models (lung, breast, kidney, liver, pancreas, ovarian cancers and melanoma) both as a monotherapy and as a synergistic combination-therapy with Cisplatin, Taxol, Gemcitabine, or Dacarbazine.

It seems that WBI-2100 possesses multiple modes of action as a novel anti-cancer drug candidate. The cytotoxicity of WBI-2100 is more selective for solid cancer cells over hematological cancer cells. Its anti-metastasis and anti-angiogenesis activities have been demonstrated in vitro and in vivo.

The unique nature of WBI-2100 is it’s property of boosting neutrophils on top of its anti-cancer activity which has been demonstrated in different animal species. Such stimulatory effects are specific for neutrophils, and other hematopoietic cells are not affected by the WBI-2100 treatment. More interestingly, when WBI-2100 is combined with the chemotherapeutic drug cyclophosphomide, chemotherapy-induced neutropenia is prevented. These combined activities of WBI-2100 as a novel cancer drug candidate that also stimulates neutrophils suggests that it has the potential of being a unique cancer chemotherapy that negates the serious side effects normally experienced by patients undergoing cancer chemotherapy. In theory, by having the unique dual activity, WBI-2100 can be combined with any chemotherapeutic cancer drugs to increase other drug’s anti-cancer efficacy and at the mean time to prevent or treat the CIN. WBI- 2100 could potentially also be developed as a small molecule treatment for CIN.